PKU HealthCare Corp Ltd (000788) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of PKU HealthCare Corp Ltd stock ¥4.42, price ¥5.47, that is 19.2% below the price, quality 70 out of 100. Rating: overvalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range ¥3.98 – ¥14.62 · fair‑value band ¥3.38 – ¥5.46 · the ¥5.47 price screens above the ¥4.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow PKU HealthCare Corp in your weekly email
Every Wednesday you see whether PKU HealthCare Corp is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PKU HealthCare Corp.,Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, pharmaceutical distribution, and medical services in China.
Show moreShow less
The company offers products in various categories, including cardiovascular and cerebrovascular, antimicrobial, antipyretic and analgesic, digestive system, oncology, anti-allergic, blood sugar and immunity regulation, mental disorder, and blood volume expansion.
It also provides tumor screening, health management, diagnosis, and treatment services. The company was formerly known as PUK International Hospital Group Southwest Synthetic Pharmaceutical Corp., Ltd. and changed its name to PKU HealthCare Corp., Ltd. in November 2013.
PKU HealthCare Corp.,Ltd. was founded in 1965 and is headquartered in Chongqing, China.
Stock analysis
PKU HealthCare Corp Ltd (000788) currently trades at ¥5.47, while our model-based Fair Value estimate is ¥4.42, 19% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ¥6.69 per share, and 9 of the 25 models we run sit above the ¥5.47 price.
Bear case: the Dividend Discount group reads lowest at ¥0.7650, and 16 of the 25 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥3.38 (bear) to ¥5.46 (bull), the price of ¥5.47 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
PKU HealthCare Corp Ltd reported revenue of 1.5B CNY in FY2025 versus 2.2B CNY in FY2021, a compound −9.8%/yr. Reported net income was 82.9M CNY in FY2025, compounding +17.7%/yr from FY2021.
Key figures
Market cap 3.3B CNY (≈ $489M) Small · P/E ratio 182.3 · P/S ratio 3.61 · EPS (TTM) ¥0.0300 · Dividend yield 3.4% · Net margin 2.3% · Return on equity 1.3% · Return on assets (EBIT) 4.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −19%, 000788 screens cheaper than that median.
Fair Value models
Bear¥3.38Fair Value ¥4.42Bull¥5.46
Price ¥5.47 · Downside -19.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.9%
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+17.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+13.9%
Dividend (yield on the price)3.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.13.9% vs 16.6%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 11%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 1.1%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.6%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −4.2% a year for the price.
Compare PKU HealthCare Corp Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 4/14 measures
Overall it trails its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside−19.2% · Below median
Profitability
Return on equity (12 months)1.3% · Below median
Return on assets4.2% · Below median
Net margin (12 months)2.3% · Below median
Operating margin (12 months)14.5% · Above median
Growth and dividend
Revenue growth (quarter YoY)−25.0% · Bottom 25%
Dividend yield (12 months)3.4% · Top 25%
Balance sheet
Debt / equity0.35× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is PKU HealthCare Corp Ltd (000788) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of ¥4.42 versus a price of ¥5.47, about 19% lower (overvalued).
What is the fair value of 000788?
Our model-based fair value for PKU HealthCare Corp Ltd is ¥4.42 (as of Nov 3, 2026), built from audited fundamentals. The current price: ¥5.47.
What is the quality score of 000788?
PKU HealthCare Corp Ltd has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PKU HealthCare Corp Ltd (000788)?
Our model-based price target is the fair value of ¥4.42 (as of Nov 3, 2026) from 25 valuation models. Cautious scenario ¥3.38, optimistic scenario ¥5.46. It is a calculation from audited fundamentals, not an analyst target.
What is the PKU HealthCare Corp Ltd stock forecast for 2026?
Our models put fair value at ¥4.42, about 19% lower versus a price of ¥5.47 (overvalued). Cautious scenario ¥3.38, optimistic scenario ¥5.46. The calculation is refreshed regularly with new filings.
What is the revenue of PKU HealthCare Corp Ltd (000788)?
PKU HealthCare Corp Ltd reported trailing-twelve-month revenue of about 904M CNY (latest available figure, as of Nov 3, 2026).
Does PKU HealthCare Corp Ltd pay a dividend?
PKU HealthCare Corp Ltd currently shows a dividend yield of 3.44% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of PKU HealthCare Corp Ltd (000788) and when is the ex-dividend date?
PKU HealthCare Corp Ltd pays a dividend of ¥0.188 per share a year, a dividend yield of 3.4%. The last ex-dividend date was Nov 3, 2026. Free cash flow covers the dividend 3.02 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into PKU HealthCare Corp Ltd (000788)?
For today's price to be fair in a discounted-cash-flow model, PKU HealthCare Corp Ltd would have to grow free cash flow by -2.6 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -5.6 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 000788 use?
Our models discount PKU HealthCare Corp Ltd at 10.4 %: a base by market capitalisation (small), damped by beta 0.15, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PKU HealthCare Corp Ltd that is -2.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has PKU HealthCare Corp Ltd (000788) delivered so far?
Over the past 5 years revenue at PKU HealthCare Corp Ltd grew -5.6 % a year. The price currently implies free-cash-flow growth of -2.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PKU HealthCare Corp Ltd (000788) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into PKU HealthCare Corp Ltd (-2.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PKU HealthCare Corp Ltd (000788)?
The free-cash-flow yield on the price is 10.38 %: that much free cash flow PKU HealthCare Corp Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PKU HealthCare Corp Ltd (000788)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PKU HealthCare Corp Ltd it is ¥4.42 per share (as of Nov 3, 2026), against a price of ¥5.47. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is PKU HealthCare Corp Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 000788 trades above its calculated fair value: price ¥5.47, fair value ¥4.42, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000788?
No. The price is what the market pays today (¥5.47); the fair value is what the company's own numbers justify (¥4.42). For PKU HealthCare Corp Ltd the two are ¥1.05 per share apart. That gap is exactly why we show both numbers side by side.
How much is PKU HealthCare Corp Ltd worth?
The market values PKU HealthCare Corp Ltd at about 3.3B CNY (market capitalisation, as of Nov 3, 2026). Per share that is ¥5.47; our models calculate a fair value of ¥4.42 per share.
What do the bullish and bearish scenarios say about 000788?
Our models span a range for PKU HealthCare Corp Ltd: cautious scenario ¥3.38, base ¥4.42, optimistic ¥5.46 per share (as of Nov 3, 2026, price ¥5.47). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 000788?
PKU HealthCare Corp Ltd trades at a price-to-earnings ratio of 182.3 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥4.42 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 83.7. Other multiples: P/B 2.1, P/S 3.6, EV/EBITDA 21.7.
How solid is the balance sheet of PKU HealthCare Corp Ltd (000788)?
Balance-sheet figures for PKU HealthCare Corp Ltd (as of Nov 3, 2026): return on equity 1.3%, debt of 0.35 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is 000788 from its 52-week high?
PKU HealthCare Corp Ltd trades at ¥5.47, about 25% below its 52-week high of ¥7.32 and 14% above the low of ¥4.81 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥4.42 is for.
Which stocks are comparable to PKU HealthCare Corp Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PKU HealthCare Corp Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price ¥5.47, calculated fair value ¥4.42 (−19%), Quality Score 70/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000788 calculated?
We run PKU HealthCare Corp Ltd through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥4.42 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. PKU HealthCare Corp Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PKU HealthCare Corp Ltd (000788)?
The closing price on Nov 6, 2026 was ¥5.47. Our model-based fair value is ¥4.42, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PKU HealthCare Corp Ltd right now?
Solid but not exceptional quality (70/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of PKU HealthCare Corp Ltd
How large is the market capitalisation of PKU HealthCare Corp Ltd (000788)?
The market capitalisation of PKU HealthCare Corp Ltd is 3.3B CNY (≈ $489M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PKU HealthCare Corp Ltd (000788)?
The price-to-sales ratio of PKU HealthCare Corp Ltd is 3.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PKU HealthCare Corp Ltd (000788)?
Earnings per share at PKU HealthCare Corp Ltd are ¥0.0300 (price ÷ EPS = P/E 182.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of PKU HealthCare Corp Ltd (000788)?
The dividend yield of PKU HealthCare Corp Ltd is 3.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of PKU HealthCare Corp Ltd (000788)?
The net margin of PKU HealthCare Corp Ltd is 2.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PKU HealthCare Corp Ltd (000788)?
The return on equity (ROE) of PKU HealthCare Corp Ltd is 1.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PKU HealthCare Corp Ltd (000788)?
On an EBIT basis the return on assets of PKU HealthCare Corp Ltd is 4.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PKU HealthCare Corp Ltd (000788)?
The operating margin of PKU HealthCare Corp Ltd is 14.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PKU HealthCare Corp Ltd (000788)?
Revenue at PKU HealthCare Corp Ltd is growing −25.0% versus a year earlier (3y avg −10.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PKU HealthCare Corp Ltd (000788)?
Earnings per share at PKU HealthCare Corp Ltd are growing −49.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does PKU HealthCare Corp Ltd (000788) hold?
PKU HealthCare Corp Ltd holds more cash than debt, 577M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch PKU HealthCare Corp Ltd in the live analysis
One click puts PKU HealthCare Corp Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026